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The mammalian target of rapamycin inhibitor everolimus (RAD001) is a successfully used immunosuppres-
sant in solid-organ transplantation. Several studies have already used RAD001 in combination with
calcineurin inhibitors after hematopoietic stem cell transplantation (HSCT). We investigated calcineurin in-
hibitorefree pre- and post-transplantation immunosuppression of RAD001 combined with mycophenolate
mofetil (MMF) in a nonmyeloablative HSCT setting. After nonmyeloablative conditioning with 2 Gy total body
irradiation, 8 dogs received HSCT from dog leukocyte antigeneidentical siblings. Immunosuppressives were
given at doses of 1.5 mg RAD001 twice daily from day 1 to þ49, then tapered until day þ56, and 20 mg/kg
MMF from day 0 to þ28, then tapered until day þ42. An historical cyclosporin A (CsA)/MMF regimen was
used in the control group. All dogs engrafted. Median platelet nadir amounted in all dogs to 0  109/L
(median, day þ10; duration <50  109/L, 22 days) and median leukocyte nadir was 1.0  109/L (range, .1 to
2.5  109/L; median, day þ13). Eventually, 5 of 8 (63%) animals rejected their grafts. Two dogs died of in-
fections on day þ19 and þ25. Pharmacokinetics of RAD001 and MMF showed median trough levels of 19.1
(range, 10.5 to 43.2) mg/L and .3 (.1 to 1.3) mg/L, respectively. The median area under the curve was 325 (range,
178 to 593) mg/L  hour for RAD001 and 29.6 (range, 7.9 to 40.5) ng/L  hour for MMF. All dogs developed
clinically mucosal viral infections during the clinical course. Compared with the control group, the level of
toxicities for RAD001/MMF increased in all qualities. Combined immunosuppression of RAD001 and MMF
after nonmyeloablative HSCT is associated with signiﬁcant toxicities, including a prolonged platelet recovery
time as well as increased infections compared to the CsA/MMF regimen.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The mammalian target of rapamycin (mTOR) kinase is a
central cell cycle regulator and its inhibition leads to G1 ar-
rest in lymphocytes as well as in various cancer cells [1].
Therefore, mTOR inhibition has been used as an immuno-
suppressive as well as an anti-cancer drug. Sirolimus (SRL)
was the ﬁrst investigated mTOR inhibitor. It has a longdgments on page 1305.
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14.06.004half-life of approximately 70 hours and, therefore, it may be
difﬁcult to adjust and dose. In a 2 Gy canine hematopoietic
stem cell transplantation (HSCT) model, Hogan et al.
demonstrated a similar engraftment by using cyclosporin A
(CsA)/SRL compared with CsA/mycophenolatemofetil (MMF)
[2]. A triple combination of SRL, CsA, andMMF only allowed a
stable engraftment in 1 of 8 dogs after using suboptimal
conditioning with 1 Gy total body irradiation (TBI) [3].
Everolimus (RAD001) is a derivative of SRL. It is used in
solid-organ transplantation for prevention of graft rejection
[4,5]. In renal transplantation, RAD001 combined with
CsA treatment was associated with signiﬁcantly improved
renal function [6,7]. RAD001 in combination with MMF
showed promising renal outcome after liver and kidneyTransplantation.
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virus infections occurrence was signiﬁcantly reduced by
combining CsA/RAD001 compared with CsA/azathioprin [10].
Former studies for HSCT used RAD001 in combination
with calcineurin inhibitors (CNIs). A clinical phase II study
with tacrolimus was canceled at an early stage because of the
high incidence of sinusoidal obstruction syndrome [11]. An
engraftment study after HSCT in canine litters using RAD001
in combinationwith CsA showed no disadvantage, compared
with treatment with CsA and MMF [12].
In addition, SRL in combination with MMF and antithy-
mocyte globulin was shown to be a feasible combination for
CNI-free graft-versus-host disease prophylaxis after an
intensive combined conditioning of 4-day chemotherapy and
4 Gy TBI [13].
We hypothesized that RAD001 might be a potential drug
to replace CNIs and minimize side effects in HSCT regimens.
Thus, we investigated the pre- and post-transplantation
combination of the mTOR inhibitor RAD001 and MMF after
2 Gy TBI in a canine littermate model, evaluating engraft-




Litters of random-bred beagles were purchased from commercial ken-
nels possessing a license for animal breeding and husbandry. All dogs were
dewormed and vaccinated against rabies, distemper, parvovirus, leptospi-
rosis, hepatitis, and parainﬂuenza virus. The selection of dog leukocyte
antigeneidentical donor/sibling pairs was based on matching for highly
polymorphic MHC class I and II microsatellite markers [14].
At the beginning of this study, the median age of the dogs was
24 months (range, 12 to 30 months), and the median weight was 16.6 kg
(range, 9.8 to 20.0 kg). This study was approved by the review board of the
State Institute for Agriculture, Food Safety, and Fishery Mecklenburg-West
Pomerania, Germany. (LALLF M-V/TSD/7221.3-1.1-013/09)
Pharmacokinetics
It was intended to keep RAD001 trough levels not lower than 8 mg/L [15].
Initial pretransplantation pharmacokinetics were performed in healthy dogs,
as previously described [12].
Brieﬂy, animals received either 1.5 mg RAD001 alone (group 1), 1.5 mg
RAD in combinationwith 20 mg/kg MMF (group 2), or 20 mg/kg MMF alone
(group 3) twice daily orally for 5 consecutive days. On the ﬁfth day, blood
samples were taken at different time points, and RAD001 concentrations
were quantiﬁed using a ﬂuorescence polarization immunoassay. Plasma
levels of mycophenolic acid (MPA), which is the active metabolite of MMF,
were measured by the CEDIA mycophenolic acid assay (Thermo Fischer
Scientiﬁc Inc.; Waltham, MA) on a Roche COBASMira Plus analyzer (Roche;
Basel, Switzerland). The study included a calculation of pharmacokinetic
parameters such as maximum concentration, time to reach maximumFigure 1. Pharmacokinetics of RAD001 (left) and MPA (right) in healthy dogs. Dogs
consecutive days. At day 5, pharmacokinetic analyses were performed and results
illustrated as solid lines.concentration, area under the curve over 12 hours (AUC0-12h), and half-life.
Pharmacokinetics of the dogs that underwent transplantation were
measured similarly at day þ5 and þ21 after HSCT.
HSCT
All dogs (n ¼ 8) received 2 Gy TBI at a dose rate of .1 Gy/minute by using
a high linear accelerator (Siemens Primus, 10 MV X-ray; Siemens; Munich,
Germany). Donor bone marrow was collected from the femur, humerus, and
iliac crest by aspiration under general anesthesia. Within 24 hours after TBI,
bone marrow was infused intravenously (day 0).
Recipients were treated with pre- and post-transplantation immuno-
suppression. Therefore, the animals received RAD001 (Certican, Novartis;
Basel, Switzerland) from day 1 to þ49 at a dose of 1.5 mg twice daily orally
and subsequently a half dose (.75 mg) until day þ56. Twenty milligrams per
kilogram MMF (CellCept, Roche) was given twice daily orally from day
0 toþ28 and continuedwith 10 mg/kg until dayþ42. Endpoints of this study
were initial and long-term engraftment, as well as the toxicity evaluation.
Long-term engraftment was deﬁned as chimerism of donor granulocytes and
peripheral blood mononuclear cells (PBMCs) after 26 weeks.
Chimerism
To evaluate the chimerism, blood samples were collected weekly until
day þ77 and at larger intervals afterwards. Samples were analyzed as pre-
viously described [16].
Toxicities
Toxicities were monitored daily during the drug administration period
(day1 untilþ56) by surveying activity, defecation, ingestion, bodyweight,
and temperature. Grades of toxicity, supportive care, and criteria of
euthanasia are speciﬁed in the supplement (Supplementary Items S1, S2).
Leucopeniawas deﬁned as<1.0109 leukocytes/L, and thrombocytopenia as
counts <50  109/L. Blood cell counts were monitored daily until cell count
recovery and then afterwards in weekly intervals. The need for blood
transfusion was deﬁned by either clinical signs of hemorrhage or platelet
counts <5  109/L. The biochemical parameters creatinine, urea, choles-
terol, triglycerides, transaminases, alkaline phosphatase, and gamma-
glutamyltransferase were assessed weekly to biweekly.
Statistics
For statistical analyses within the treatment group, the Wilcoxon
matched-pairs signed rank test was used. Differences between groups were
evaluated by the Mann-Whitney U-test. To describe the distribution of data,
medians and ranges were stated. Probabilities of P < .05 were considered to
be signiﬁcant.
RESULTS
Pharmacokinetics and Toxicities in Healthy Dogs
Results of pharmacokinetics are displayed in Figure 1 for
the combined RAD001/MMF application (group 2) and in the
supplement (Supplementary Table S1) for all groups. After
receiving RAD001 alone (group 1), median trough level was
15.6 mg/L (range, 11.5 to 21.3 mg/L). The combination with
MMF (group 2) resulted in a comparable RAD001 medianreceived RAD001 (1.5 mg twice daily) and MMF (20 mg/kg twice daily) for 5
are displayed for each dog. Median RAD001 (left) and MPA (right) levels are
Table 1
Overview of Grafts and Maximal Donor Chimerism
Dog No. Graft Cell Counts Maximal Donor Chimerism
CD34þ, 106/kg TNC, 108/kg CD3þ, 107/kg Granulocytes, % (d) PBMCs, % (d)
I 6.3 6.5 4.4 96 (48) 85 (34)
II 1.3 2.0 1.6 79 (14) 36 (21)
III 5.0 4.0 3.9 90 (14) 52 (21)
IV .7 2.1 3.0 89 (35) 63 (28)
V 4.8 4.1 2.5 71 (14) 65 (14)
VI 3.6 3.7 2.4 64 (21) 43 (28)
VII 6.5 4.3 1.5 93 (28) 85 (28)
VIII 2.4 3.6 2.1 33 (14) 3 (7)
Median 4.2 3.8 2.5 84 (18) 58 (25)
TNC indicates total nucleated cells.
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given in combination (group 2), the median MPA AUC(0-12h)
increased signiﬁcantly from 24.1 mg/L  hour (range, 11.8 to
36.5 mg/L  hour) alone (group 3) to a median of 45.2 mg/
L  hour (range, 36.9 to 72.3 mg/L  hour) (P ¼ .029).
Assessment of hematotoxicity showed a mild decrease in
platelet counts in all groups. The most apparent reduction
starting at 290  109/L at day 0 to 161  109/L at day 8 was
observed in group 2 (data not shown). No further clinically
relevant toxicities were observed.Engraftment and Hematologic Recovery after HSCT
Transplantation and chimerism data are shown in Table 1
and Figure 2. All dogs engrafted. Median maximal donor
chimerism for granulocytes was 84% (range, 33% to 96%) at
median day þ18. Median maximal donor PBMC chimerism
was 58% (range, 3% to 85%) at median day þ25. Dog I
developed a stable high donor chimerism until the end of the
observation period. Five of 8 animals rejected their grafts and
recovered with autologous marrow at median day þ91
(range, 63 to 239). Dogs III and VIII died unexpectedly from
infections, despite daily check of health status, on days þ25
and þ19, respectively. In spite of supportive therapy, both of
them developed mucosal viral infections with ulcerations
and fever up to 41.5C. Dog III died at day þ25 with a high
donor chimerism of 90% granulocytes and 52% PBMCs. Dog
VIII showed a rising donor percentage of 33% for gran-
ulocytes and 3% for PBMCs, before dying at day þ19.
The hematological recovery after HSCT is displayed for
the leukocyte and platelet counts in Figure 3. The median
leukocyte nadir was 1.0  109/L (range, .1 to 2.5  109/L) at
the median dayþ13 (range, 7 to 24). Dogs III and VIII showed
a prolonged leucopenia of 8 and 15 days, respectively, beforeFigure 2. Granulocytes (left) and PBMC (right) donor chimerism after HSCT. Chimerism
larger intervals. This ﬁgure shows the percentage of hematopoietic donor chimerismdying, compared with the leucopenia duration of the rest,
with median 0 days (range, 0 to 5 days). The platelet nadir of
all dogs was 0  109/L. The duration of thrombocytopenia
was a median of 22 days (range, 11 to 29 days). The median
time to platelet recovery was 36 days (range, 29 to 36 days).
Seven of 8 recipients required whole blood transfusions to
prevent hemorrhage (median, 2.5 transfusions/dog). Median
hemoglobin nadir was 5.3 mmol/L (range, 3.6 to 9.9 mmol/L)
at median day þ35 (data not shown).Post-Transplantation Pharmacokinetics
During the course of the study, RAD001 and MMF phar-
macokinetics were analyzed on day þ5 and þ21 after HSCT
(Figure 4, Supplementary Table S2). All recipients showed
RAD001 trough levels above the lower concentration limit of
8.0 mg/L (median, 19.1 mg/L; range, 10.5 to 43.2 mg/L). The
RAD001 morning dose was decreased to 1 mg for dog V
because of a high AUC value (571 ng/mL  hour) at day þ5.
Additionally, MMF administration was prematurely termi-
nated at day þ29 and RAD001 dose was adjusted to 1.0 mg
twice daily in dog VII because of infections. No signiﬁcant
differences of pharmacokinetic parameters between day þ5
and þ21 were observed.Toxicities
Cholesterol values increased signiﬁcantly but stayed
within normal limits. Alkaline phosphatase showed values
beyond the upper range during the trial period, starting at
median 77 units [U]/L at day 0 and maximal level of 139 U/L
at day þ21 (normal range <108 U/L). No further increase of
other blood parameters could be observed. At day þ56, all
altered parameters recovered to pretransplantation values
after tapering the immunosuppressives.analyses were performed after HSCT weekly until day þ77 and afterwards in
for granulocytes (left) and PBMCs (right) after HSCT. yDeceased during course.
Figure 3. Hematologic recovery in dogs after HSCT. Median cell counts of leukocytes (A) and platelets (B) were measured after HSCT and immunosuppression by
RAD001 (1.5 mg twice daily) and MMF (20 mg/kg twice daily). Data were compared with our historical CsA/MMF control group (CON).
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occurred in all recipients (Supplementary Figure S1). Dogs III
and VIII died unexpected without reaching criteria for
euthanasia, as outlined in the supplement. During the
following autopsy, multiple lesions in mouth and sporadic
gastrointestinal lesions were found. No further cause of
death could be proven.
Additionally, 7 of 8 dogs showed transient temperatures
>40C. Four of 8 recipients showed reduced activity ( grade
2) for a median of 5 days (range, 2 to 13 days). All dogs
demonstrated reduced appetite. In 5 recipients, parenteral
nutrition was required. The MMF dose was adjusted
repeatedly, according to the actual individual weight.
DISCUSSION
Herein, we investigated the pre- and post-transplantation
combination of the mTOR inhibitor RAD001 and MMF after
2 Gy TBI in a canine littermate model.Figure 4. Pharmacokinetic proﬁles of RAD001 and MPA after HSCT. RAD001 was giv
tapered by half dose until day þ56. MMF (20 mg/kg twice daily) administration wa
Pharmacokinetic proﬁles were tested at day þ5 and þ21 for both drugs. Results areFirst, we characterized the pharmacokinetic properties of
the compounds in healthy dogs. To replace CNI, trough levels
of RAD001 between 6 and 10 mg/L or 8 and 12 mg/L were
tested in kidney and liver transplantation [8,9]. Thus, we
focused in our HSCT model on a RAD001 trough level above
8 mg/L [15]. Our starting dose of 1.5 mg RAD001 twice daily
rapidly exceeded this minimal trough level. Therefore, we
used it as the starting dose in our transplantation group. The
median half-life of RAD001 in this model amounted to
13.6 hours. In contrast to pharmacokinetic studies in
humans, these observed values are remarkably short but are
comparable to the half-life of former studies in dogs [12,17].
The MPA concentration in healthy dogs increased rapidly to
the maximum concentration value in all recipients and
showed similar characteristics in dogs, as previously
described [18-20]. Of note, a mild decrease in platelet counts,
which was also noted previously in RAD001-based CNI-free
immunosuppressive regimens, was observed [7].en from day 1 to þ49 at a starting dose of 1.5 mg twice daily orally and was
s performed from day 0 to þ28 and continued with 10 mg/kg until day þ42.
displayed as medians (solid lines), 25 quantile, and 75 quantile (dotted lines).
C. Machka et al. / Biol Blood Marrow Transplant 20 (2014) 1301e1306 1305All 8 dogs in this study initially engrafted, but toxic effects
were signiﬁcant. The initial engraftment levels in our study
were comparable to former studies with 2 Gy TBI [2,12,21].
However, only 1 dog demonstrated a long-term engraftment.
When compared with other studies administrating CNI in
combination with MMF, the herein observed long-term
engraftment appears lower [22]. Hogan et al. showed an
engraftment in 5 of 6 dogs using CsA combined with the
mTOR inhibitor SRL after 2 Gy TBI [2]. Additionally, RAD001
used in lower concentrations combined with CsA was re-
ported to lead to a long-term engraftment in 4 of 9 dogs after
HSCT [12]. Herein, 4 dogs rejected their grafts in the ﬁrst
9 weeks after HSCT, 1 dog rejected within 30 weeks, and 2
dogs died during the course, despite intensive supportive
care. The time-wise correlation of dose tapering and
decrease of donor percentage may indicate a correlation
between the end of the immunosuppressive treatment and
graft rejection.
The median RAD001 trough level of 19.1 mg/L after HSCT
clearly remained in the targeted range; however, it was
higher compared with RAD001 concentrations applied in
previous studies [7-9]. The resulting higher immunosup-
pression might be one reason for the poor engraftment rate
observed in the present study.
No drug accumulation of RAD001 and MPA could
be detected between day þ5 and þ21. This data is in accor-
dance with previous results of RAD001 in combination with
CsA [23].
Common side effects of mTOR inhibitors on blood pa-
rameters are increased levels of creatinine, cholesterol, and
triglycerides and decreased leukocyte and platelet counts
[7,17,23]. One of the main obstacles in our study was
enhanced thrombocytopenia. Compared with other immu-
nosuppressive regimens, our RAD001/MMF group showed a
delayed recovery time and an increased requirement for
blood transfusions [2,12]. Similar to our ﬁndings, the use of
RAD001 in CNI-free solid-organ transplantation showed
more frequent drug-related toxicity compared with CNI
regimens [7-9]. However, no sinusoidal obstruction syn-
drome was observed in our study [11].
Mucosal lesions occurred in all dogs with a higher inci-
dence in the deceased dogs than in the surviving animals.
This adverse event of RAD001 was previously observed in
solid-organ transplantation and treatments of cancer pa-
tients, as well [7,9,24]. Ferte et al. described a dose-related
effect of RAD001 on mucosal ulcerations [25]. However, in
our study, clinical signs suggested a viral genesis. The lesions
may have led to a variable drug uptake and, thus, to a higher
variability in pharmacokinetics.
In conclusion, the combination of high dose RAD001 and
MMF as pre- and post-transplantation immunosuppression
in a nonmyeloablative HSCT led to substantially increased
toxicity parameters, in particular mucosal lesions and pro-
longed thrombocytopenia, which are typical for high
RAD001 levels. Consequently, this drug combination appears
to be inferior compared with established immunosuppres-
sive regimens used in nonmyeloablative HSCT. To prevent
graft rejection, immunosuppression may be administered
longer and amore individually adjusted dose of RAD001may
eliminate high pharmacotoxicity.ACKNOWLEDGMENTS
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